Cardio Diagnostics Holdings, INC 8-K filings

Cardio Diagnostics Holdings, Inc. is holding an investor conference call to discuss corporate updates, recent clinical data, reimbursement progress, and strategic priorities for its precision cardiovascular medicine platform.

Cardio Diagnostics Holdings, Inc. stockholders approved the election of seven directors, a significant share issuance proposal, and the ratification of its independent auditor at the annual meeting.

Cardio Diagnostics Holdings, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, securing its continued listing on The Nasdaq Stock Market.

Cardio Diagnostics Holdings, Inc. implemented a 1-for-30 reverse stock split, effective May 13, 2025, to meet Nasdaq's minimum bid price requirement.

Cardio Diagnostics Holdings Inc. is leveraging epigenetics and artificial intelligence to revolutionize cardiovascular medicine with a suite of diagnostic and risk assessment tools.

Cardio Diagnostics Holdings, Inc. has received a second extension from Nasdaq to regain compliance with the minimum bid price requirement, now until June 2, 2025.

Cardio Diagnostics Holdings held its annual meeting, where shareholders voted on key proposals including the election of directors, a reverse stock split, and the issuance of additional shares.

Cardio Diagnostics Holdings, Inc. has received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock price has remained below $1.00 for 30 consecutive business days.

Cardio Diagnostics Holdings Inc. released an investor presentation detailing their AI-driven approach to cardiovascular disease prevention and detection using epigenetics.

Cardio Diagnostics Holdings has successfully closed a private placement, issuing units consisting of common stock and warrants, raising $1 million for working capital and general corporate purposes.

Cardio Diagnostics Holdings has entered into an agreement to potentially sell up to $17 million of its common stock through an at-the-market offering.